# An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

> **NCT01818921** · PHASE2 · COMPLETED · sponsor: **Zafgen, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Obesity
- Over-weight
- Prader-Willi Syndrome

## Interventions

- **DRUG:** ZGN-440 sterile diluent
- **DRUG:** 1.2 mg ZGN-440 for injectable suspension
- **DRUG:** 1.8 mg ZGN-440 for injectable suspension

## Key facts

- **NCT ID:** NCT01818921
- **Lead sponsor:** Zafgen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818921, "An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01818921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*